---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-032547"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2023-04-25T23:59:59+00:00"
generated_at: "2026-06-16T16:52:13.264377+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Allarity raises $7.5M in public offering; restructures debt and preferred stock with 3i, LP

## Summary
- Gross proceeds $7.5M from offering of 2.87M shares, pre-funded warrants for 7.13M shares, and common warrants for 10M shares at $0.85.
- 3i, LP provided $350K loan converted to 486 Series A shares; exchanged Series C for 4,027 Series A shares.
- Company paid $3.35M to cancel all outstanding debt to 3i and repurchased 1,550 Series A shares for $1.65M.
- Series A preferred stock amended: redemption right and dividend eliminated; conversion price set at $0.75.
- Exchange warrant issued to 3i for 12.6M common shares at $0.75 exercise price.

## SEC filing metadata
- accession: 0001213900-23-032547
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2023-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/0001213900-23-032547-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/ea177302-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-032547
- JSON: https://secwatch.observer/filing/0001213900-23-032547.json
- Plain text: https://secwatch.observer/filing/0001213900-23-032547.txt

## Key facts
- Governance Changes
  Allarity Therapeutics, Inc.: Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock to eliminate redemption right and dividend and adjust conversion price (effective 2023-04-21).
  - Change: charter amendment
  - Effective: 2023-04-21
  source text: On April 21, 2023, in connection with the transactions contemplated under the Exchange Agreement, the Company filed an Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock of the Company (the “Amended and Restated Series A COD”) with the Secretary of State of the State of Delaware (the “Delaware Secretary of State”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/0001213900-23-032547-index.htm
- Material Agreements
  Allarity Therapeutics, Inc. entered into Modification and Exchange Agreement with 3i, LP (effective 2023-04-20).
  - Action: entry
  - Counterparty: 3i, LP
  - Effective: 2023-04-20
  source text: On April 20, 2023, the Company entered into a certain Modification and Exchange Agreement (the “Exchange Agreement”) with 3i
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/0001213900-23-032547-index.htm
- Material Agreements
  Allarity Therapeutics, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at a cash fee equal to 7.0% of the aggregate gross proceeds of the Offering and up to $150,000 in aggre (effective 2023-04-19).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: A.G.P./Alliance Global Partners
  - Value: a cash fee equal to 7.0% of the aggregate gross proceeds of the Offering and up to $150,000 in aggre
  - Effective: 2023-04-19
  source text: Concurrently with the Purchase Agreement, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“AGP”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/0001213900-23-032547-index.htm
- Material Agreements
  Allarity Therapeutics, Inc. entered into Securities Purchase Agreement with certain purchasers valued at aggregate gross proceeds of approximately $7.5 million (effective 2023-04-19).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain purchasers
  - Value: aggregate gross proceeds of approximately $7.5 million
  - Effective: 2023-04-19
  source text: The Securities were sold pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with each purchaser identified on the signature pages thereto
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/0001213900-23-032547-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.